Higher HR, ER, and PR statuses were noted in HER2-low tumors compared to HER2-zero cancers, associated with lower histological grades and lower Ki-67 levels, which is consistent with previous reports (Won et al., 2022; Chen et al., 2024). The gene discussed is ERBB2; the disease is cancer.